Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Here you go :
https://www.youtube.com/watch?v=ZPjiX-VY3Cg
Anyone got a link for the presentation
I think it’s a better more open presentation than the last one in all fairness…
No mention of headway in the colonies
However they may just pull the rabbit out of the hat!!
I bet the Chairman is delighted with his purchase how to make 122k in to 61k. give it to Greg to manage.
Technically yes but execution has to be spot on from here to make that happen.
What is the likelihood of that?
I thought that.... Says they have had the scissors out to cut costs..
Did he just say in a long-winded way say they have sufficient cash to get them to positive operating cash flow in 2025? nb. as a result of some fundamental changes to wc mgmt, etc. Surely this is basic stuff so why wasn't it done before?
Almost definitely won't, or a nonsense response, shambles management
Can sell all 500,000 but not get any to buy
It looks like you just took the last lot of shares available at 3p. Nothing left now at 3p on HL & IG platforms
@ 3p this is way undervalued and i am confident the market will wake up to this soon.
I am sure Greg will be as enthusiastic as ever despite the decimation of our SP on his watch.
Interesting to see if he responds to questions regarding progress in S Korea,Canada & China- or any other incisive questions
CEO, Greg Madison, and CFO, Santosh Shanbhag, will be hosting a live online presentation relating to the trading update via the Investor Meet Company platform at 14:00 (GMT) on Thursday 22 February 2024.....should be an interesting meeting
What a bounce back 4.5% woohoo! I'm not buying another share on the wild west of AIM again, over to the US market for me where there's some serious liquidity...
22 Feb 2024
Gateshead-based commercial stage pharmaceutical firm Shield Therapeutics has revised its breakeven plans, but hailed a period of progress.
In a trading update for the year ended 31 December 2023, Shield Therapeutics said that it expects to turn cash flow positive in the second half of 2025, instead of its initial target of year-end 2024.
The update follows the company identifying that its projection methodology used by its third-party data provider had resulted in an overstatement of total prescriptions in 2023.
"This development was partly responsible for the group not achieving previously indicated guidance of total prescriptions in FY23 of 100k to 130k", Shield said.
"With these revised prescription numbers, Shield is revisiting its previously communicated guidance and plans to provide additional updates at the time of the company's final results, expected to be published in April 2024", it added.
In spite of this, total 2023 revenue and income stood at $17.5m, which was a 2.8x increase over FY22.
Cash at the end of December was $13.9m.
Chief executive Greg Madison said: "The progress made in the market in 2023 has shown us that the opportunity for Accrufer continues to be significant.
"Quarterly prescription numbers grew throughout the year and we saw a significant improvement in the average net selling price in the second half.
"I'm also excited our new CFO, Santosh Shanbhag, has joined the team bringing both strategic and financial leadership to our organisation. Our partnership with Viatris continues to progress very well and we remain steadfast in our goal to make Accrufer the oral iron of choice for patients."
Link: https://shorturl.at/twCD5
Also, there was no update on South Korea, Canada, China etc.
I am going to try and watch it. They need to restore confidence..
2pm is CEO and CFO online presentation relating to the trading update.
I'll be keen to see what impression that makes on any who are able to attend and feedback.
4P today. Fill yer boots!
Rally time
Key line for me - Previously reported Group financials including revenues, net revenues per Accrufer® prescription, and compliance with financial covenants on the Group's debt instrument are not affected by this change
500,000 shares
It is a no brainer
Rising sales {if below forcasts so what]
Excellent sales price
Popular and needed medical product
BEST OF AT AN ALL TIME LOW
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s third-quarter trading update for Accrufer in the US market shows its tie-up with Viatris and expanded sales team are “bearing fruit”, according to analysts.
Accrufer is a non-salt based oral therapy used to treat iron deficiency in adults.
Analysts at Cavendish said key performance indicators such as total scrips, new scrips, retention rate, and net realised price are all showing significant improvement compared to the first half of 2023.
The number of US representatives promoting Accrufer increased from 16 to 30 in the first quarter of 2023, and by May 2023, a total of 100 had been trained to sell the product.
Third quarter unaudited sales were US$4.1 million, above the broker’s forecasts of US$3.6 million, and the company said trading is in-line with expectations.
Link: https://www.proactiveinvestors.co.uk/companies/news/1036099/shield-therapeutics-is-bearing-fruit-says-cavendish-1036099.html